 |
|
|
| |
Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Jose Ramon Arribas,1 Arun J. Sanyal,2 Alex Soriano Viladomiu,3 Bum Sik Chin,4 Shirin Kalimuddin,5 Stefan Schreiber,6 Emon Elboudwarej,7 Yuan Tian,7 Robert H. Hyland,7 Devi SenGupta,7 Anand Chokkalingam,7 Anu O. Osinusi,7 Diana M. Brainard,7 Christoph Lübbert,8 David Chien Boon Lye,9 Judith A. Aberg,10 Enrique Navas Elorza,11 Karen T. Tashima,12 Mark McPhail13
1Hospital Universitario La Paz, Madrid, Spain; 2VCU Medical Center, Richmond, VA; 3Hospital Clínic de Barcelona, Spain; 4National Medical Center, Seoul, Republic of Korea; 5Singapore General Hospital, Singapore; 6Universitätsklinikum Schleswig-Holstein, Kiel, Germany; 7Gilead Sciences, Inc., Foster City, CA; 8Klinik für Infektiologie/Tropenmedizin, Nephrologie und Rheumatologie, Klinikum St. Georg, Leipzig, Germany; 9National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore; 10Icahn School of Medicine at Mount Sinai, New York, NY; 11Hospital Universitario Ramón y Cajal, Madrid; 12The Miriam Hospital, Providence, RI; 13King's College Hospital, London, UK
References: 1. Gordon CJ, et al. J Biol Chem 2020;295:6785-97; 2. Goldman JD, et al. N Engl J Med 2020 May 27;NEJMoa2015301; 3. Spinner CD, et al. JAMA 2020;324:1048-57; 4. US Food and Drug Administration. Fact Sheet for Patients and Parent/Caregivers Emergency Use Authorization (EUA) of Hydroxychloroquine Sulfate for Treatment of COVID-19 in Certain Hospitalized Patients; 3/28/20; revoked 6/15/20
|
| |
|
|
|
|
|
